<?xml version="1.0" encoding="UTF-8"?>
<ref id="B38-vaccines-07-00070">
 <label>38.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hahn</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Kahn</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Baldanti</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Koszinowski</surname>
    <given-names>U.K.</given-names>
   </name>
   <name>
    <surname>Revello</surname>
    <given-names>M.G.</given-names>
   </name>
   <name>
    <surname>Gerna</surname>
    <given-names>G.</given-names>
   </name>
  </person-group>
  <article-title>The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild type characteristics</article-title>
  <source>J. Virol.</source>
  <year>2002</year>
  <volume>76</volume>
  <fpage>9551</fpage>
  <lpage>9555</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.76.18.9551-9555.2002</pub-id>
  <pub-id pub-id-type="pmid">12186938</pub-id>
 </element-citation>
</ref>
